Translating Complex Cell and Gene Therapies into the Clinic

Cell and gene therapies (CGTs) are among the most promising and fastest-evolving areas of modern medicine. Spanning a wide spectrum of modalities, including in vivo viral vectors, CRISPR-based gene-modified cells, expanded cells for regenerative medicine, and CAR-T therapies for immune modulation - CGTs offer the potential to treat diseases that have long lacked effective options.

Unlike more established biologic modalities such as recombinant proteins, monoclonal antibodies, or antibody-drug conjugates, CGTs are defined by their diversity. Each therapy often requires a highly customized manufacturing approach, shaped by the underlying biology, vector system, cell type, and intended clinical application. This complexity introduces significant challenges when transitioning from early research into clinical manufacturing, where regulatory compliance, reproducibility, and scalability become essential.

For companies seeking to move a novel CGT into the clinic, the choice of manufacturing partner is therefore critical. A capable partner must not only provide compliant production capacity, but also the technical expertise to translate an early-stage process into a robust, cGMP-ready workflow suitable for human administration.

Bramble Bio is a contract development and manufacturing organization (CDMO) well placed to meet this need. Part of the FamiCord Group, Bramble Bio specializes in developing early manufacturing processes into cGMP-compliant workflows, where we produce drug substance and product for Phase I and Phase II clinical trials.

From Early Stage to Clinical Manufacturing

Bramble Bio’s origins are closely linked to translational research and early clinical development. Built on expertise developed within the FamiCord Group, the organization was established to bridge the gap between laboratory-scale innovation and regulated clinical manufacturing. This background has shaped Bramble Bio’s practical, development-driven approach, emphasizing collaboration with therapy developers from the earliest stages of process design.
Rather than offering standardized, one-size-fits-all solutions, Bramble Bio works closely with clients to assess existing protocols, identify potential bottlenecks, and redesign processes with cGMP requirements in mind. This includes considerations such as raw material selection, closed and automated systems, process controls, and documentation—elements that are often overlooked in early research but are critical for regulatory success.

An Integrated CGT Service Offering

Bramble Bio provides a suite of services designed to support CGT programs through early clinical development. These services span the full manufacturing lifecycle, enabling clients to work with a single partner as their programs mature.

Manufacturing services form the core of Bramble Bio’s offering, with capabilities focused on the production of cGMP-compliant cell and gene therapy products for clinical use. This is complemented by cell sourcing services, ensuring that starting materials meet quality, traceability, and regulatory requirements.

Consulting services play a key role in supporting clients who are navigating the transition from research to the clinic. Bramble Bio’s teams provide guidance on process development, regulatory readiness, and manufacturing strategy, helping developers align technical decisions with long-term clinical and commercial goals.

Analytical services are a cornerstone of cell and gene therapy (CGT) development, providing critical evidence of product identity, purity, safety, viability, and integrity. We support assay transfer, development, and validation - including potency assays aligned with mechanism of action. A phase-appropriate analytical strategy enables robust product characterization and supports a smoother regulatory submission.

Cryo-logistics becomes increasingly complex for products in Phase II and beyond, but making a few critical decisions even before clinical Phase I can significantly simplify this, adding flexibility and reducing risk at launch. Bramble Bio can help provide guidance and our integrated GDP logistics function leverages our 15 pan-European facilities to maintain product integrity and regulatory compliance. You can read a brief article on this topic on our website here.

Supporting the Next Generation of CGTs

As the CGT field continues to expand, the importance of specialized development and manufacturing expertise will only increase. Early clinical success depends not just on therapeutic concept, but on the ability to reliably and compliantly manufacture complex biological products.

By combining development-focused thinking with cGMP manufacturing capabilities, Bramble Bio positions itself as a partner for innovators seeking to translate promising cell and gene therapies into early-stage clinical reality. Through close collaboration, technical depth, and an understanding of CGT-specific challenges, the organization supports developers at a critical stage in the journey from bench to bedside.

Contact us to have a discussion with our experts on how we can advance your cell and gene therapy manufacturing process into clinic.